Previous studies have shown that Navitoclax synergize effectively with targeted therapies such as EGFR inhibitors in NSCLC and MEK inhibitors in KRAS mutant cancers and BRAF mutant melanoma56–58. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.